Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia GlobeNewswire July 07, 2025 Breakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to […]

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21 GlobeNewswire July 07, 2025 NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS)

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development GlobeNewswire July 07, 2025 WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief

Lancaster Strengthens Gold Portfolio with Completion of Lake Cargelligo Acquisition GlobeNewswire July 07, 2025 VANCOUVER, British Columbia, July 07, 2025 (GLOBE NEWSWIRE) — Lancaster Resources Inc. (CSE:LCR) (OTC Pink:LANRF) (FRA:6UF0) (“Lancaster“, the “Company“) is pleased to announce the completion of its acquisition of 100% of the Lake Cargelligo Gold Project, a district-scale exploration property in

Western Financial Group Wins 2025 Canadian Business Excellence Award Award recognizes Western's customer-first strategy, innovative leadership, and deep community roots GlobeNewswire July 07, 2025 HIGH RIVER, Alberta, July 07, 2025 (GLOBE NEWSWIRE) — Western Financial Group is proud to announce it has been named a recipient of the 2025 Canadian Business Excellence Award for Private

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenstrom Macroglobulinemia Regulatory momentum builds for bexobrutideg with multiple designations across the United States and EU, Including EMA PRIME and FDA Fast Track for CLL/SLL GlobeNewswire July 07, 2025 SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) —

Aya Gold & Silver Reports High-Grade Boumadine Exploration Results, Expands Imariren to 1km and Identifies New High-Grade Asirem Zone to the West GlobeNewswire July 07, 2025 MONTREAL, July 07, 2025 (GLOBE NEWSWIRE) — Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to announce new high-grade drill exploration results

Inventus Reports 4.10 gpt Gold and 1.78 Metre Average in 30 Drill Holes Within 6 Metres of Surface at the 10,000-Tonne Trench 1 Bulk Sample Site GlobeNewswire July 07, 2025 TORONTO, July 07, 2025 (GLOBE NEWSWIRE) — Inventus Mining Corp. (TSXV: IVS) (“Inventus” or the “Company”) is pleased to announce final assays from grade-control drilling

Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference GlobeNewswire July 07, 2025 LOS ALTOS, Calif., July 07, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer,

Shoals Technologies Group, Inc. Announces Second Quarter 2025 Earnings Release Date and Conference Call GlobeNewswire July 07, 2025 PORTLAND, Tenn., July 07, 2025 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (the “Company”) (Nasdaq: SHLS) today announced that the Company will release its second quarter 2025 results before market open on Tuesday, August 5, 2025, to